Sec Form 3 Filing - White Christopher G @ OCULAR THERAPEUTIX, INC - 2021-10-01

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person White Christopher G 2. Issuer Name and Ticker or Trading Symbol OCULAR THERAPEUTIX, INC [ OCUL] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Business Officer (Last) (First) (Middle) C/O OCULAR THERAPEUTIX, INC.,, 24 CROSBY DRIVE 3. Date of Earliest Transaction (MM/DD/YY) 10/01/2021 (Street) BEDFORD, MA01730 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (right to buy) $ 5.13 ( 1 ) 07/08/2029 Common Stock 38,751 D Stock Option (right to buy) $ 4.39 ( 2 ) 01/29/2030 Common Stock 73,309 D Stock Option (right to buy) $ 18.31 ( 3 ) 02/16/2031 Common Stock 153,500 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other White Christopher G C/O OCULAR THERAPEUTIX, INC., 24 CROSBY DRIVE BEDFORD, MA01730 Chief Business Officer Signatures /s/ Donald Notman, Attorney-in-Fact for Christopher G. White 10/08/2021 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The reporting person was granted an option to purchase 60,000 shares on July 9, 2019, vesting over four years, with 1/4 of the shares underlying the option vesting on July 9, 2020, and 1/48 of the shares underlying the option vesting monthly thereafter. Prior to becoming subject to Section 16, the reporting person partially exercised this option to purchase 21,249 shares and sold the shares of common stock received upon such exercise in open market sales. ( 2 )The reporting person was granted an option to purchase 92,600 shares on January 30, 2020, vesting over four years, with 1/48 of the shares underlying the option vesting monthly beginning on the one-month anniversary of the date of grant. Prior to becoming subject to Section 16, the reporting person partially exercised this option to purchase 19,291 shares and sold the shares of common stock received upon such exercise in open market sales. ( 3 )The option was granted on February 17, 2021, vesting over four years, with 1/48 of the shares underlying the option vesting monthly beginning on the one-month anniversary of the date of grant.

Remarks: Exhibit List Exhibit 24 - Power of Attorney

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.